What is the recommended treatment regimen for an infection caused by Candida rugosa?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: June 10, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Treatment of Candida rugosa Infection

For invasive Candida rugosa infections, initiate treatment with an echinocandin (anidulafungin 200 mg loading dose then 100 mg daily, micafungin 100 mg daily, or caspofungin 70 mg loading dose then 50 mg daily) as first-line therapy, given the frequent azole resistance of this species. 1

Key Clinical Considerations

Why Echinocandins Are Preferred

C. rugosa is a distinctive emerging pathogen with critical treatment implications:

  • Azole resistance is common: Up to 21% of isolates demonstrate fluconazole resistance 2, making empiric azole therapy unreliable
  • Amphotericin B may be refractory: Multiple case series report treatment failures despite amphotericin B therapy 3, with high mortality rates even when used
  • Echinocandins show consistent activity: The 2025 global guideline strongly recommends echinocandins for candidemia in high-risk patients 1, and C. rugosa typically remains susceptible to this class 4

Treatment Algorithm

Initial therapy (first 48-72 hours):

  • Start echinocandin immediately upon identification or strong suspicion of C. rugosa
  • Remove central venous catheter within 48-72 hours if present 1 - this is critical as C. rugosa is strongly associated with catheter-related infections 4
  • Obtain daily blood cultures until three consecutive negative days 1

Subsequent management:

  • Review susceptibility testing results when available 1
  • Consider step-down to fluconazole 400-800 mg daily ONLY if: (1) isolate is susceptible, (2) patient demonstrates clear clinical response, and (3) blood cultures have cleared 4
  • Continue therapy for 2 weeks after documented clearance from bloodstream and resolution of attributable signs 1

Critical Pitfalls to Avoid

Do not use fluconazole empirically for suspected or confirmed C. rugosa - the resistance rates are too high and mortality consequences too severe 2, 3. The one exception is step-down therapy after documented susceptibility and clinical improvement.

Do not rely on amphotericin B as first-line therapy despite historical use. Multiple outbreak reports document refractory infections and high mortality even with amphotericin B treatment 3. While some older data suggest amphotericin B susceptibility 5, clinical failures are well-documented in more recent literature 3.

Source Control is Non-Negotiable

C. rugosa has strong associations with:

  • Central venous catheters (remove early) 1, 4
  • Total parenteral nutrition 4
  • Invasive medical procedures 3

The 2025 guideline strongly recommends catheter removal as early as possible (within 48-72 hours) when safe to do so 1. This is not optional - source control significantly impacts mortality outcomes.

Special Populations

Critically ill/ICU patients: The association between C. rugosa and trauma/ICU settings is well-established 2. These patients warrant aggressive echinocandin therapy given the 68% mortality rate reported in trauma cohorts 2.

Immunocompromised hosts: While C. rugosa can infect immunocompetent patients 3, those with hematologic malignancies or neutropenia require particular vigilance. The 2021 consensus guidelines for hematology/oncology settings reinforce echinocandins as first-line for high-risk invasive candidiasis 6.

Duration and Monitoring

  • Continue antifungal therapy for minimum 2 weeks after blood culture clearance 1
  • Obtain daily surveillance blood cultures until three consecutive negative results 1
  • If blood cultures remain positive at day 5, repeat search for uncontrolled sources or intravascular foci 1
  • Consider ophthalmologic examination and imaging for metastatic complications in persistent candidemia 1

References

Related Questions

What is the recommended treatment regimen for Candida ciferri infection in an adult?
When is treatment indicated for Candida infection in a cyclist (e.g., due to moisture from tight cycling clothing)?
Can antibiotic use cause candidiasis after completing therapy?
What is the best systemic antifungal to administer intravenously for cutaneous Candida infection?
What alternative therapy can be used instead of fluconazole 200 mg daily for a wound infection that is positive for yeast?
Which bedside ultrasound finding supports a diagnosis of septic shock?
What are the histopathological features of the urticarial stage of bullous pemphigoid?
In a trauma patient, what does an abnormal continuation of the spinous line on imaging indicate?
What is the recommended echinocandin dosing for an adult with invasive Candida rugosa infection, including loading and maintenance doses and adjustments for renal or hepatic impairment?
In an elderly patient (>65 years) with atrial fibrillation who has had a subdural haematoma, when and how should anticoagulation be restarted, and which agents and dosing are preferred?
How can laryngospasm be prevented during extubation?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.